← Back to Treatments
🏅 FDA Orphan Designation

Beqvez

fidanacogene elaparvovec-dzkt

Manufacturer: Pfizer Inc.

Indicated for:
Moderate hemophilia BOrphan

FDA-Approved Indications (1)

Moderate hemophilia BOrphan Designation

treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who: Currently use factor IX prophylaxis therapy, or; Have current or historical life-threatening hemorrhage,…

Indications & Usage

treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who: Currently use factor IX prophylaxis therapy, or; Have current or historical life-threatening hemorrhage, or; Have repeated, serious spontaneous bleeding episodes, and; Do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test

💙 Support Programs

View all →
Beqvez
Pfizer Inc.
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.